Vanguard disaggregates holdings; reports 0 shares in Biogen (NASDAQ: BIIB)
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G/A
Rhea-AI Filing Summary
Biogen Inc. — The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting zero shares of Biogen common stock and 0% beneficial ownership following an internal realignment.
The filing states certain Vanguard subsidiaries will report holdings separately under SEC Release No. 34-39538, effective after the January 12, 2026 realignment. The report is signed by Ashley Grim, Head of Global Fund Administration, dated 03/26/2026.
Positive
- None.
Negative
- None.
FAQ
What did The Vanguard Group report for BIIB in Amendment No. 13?
Vanguard reported 0 shares and 0% beneficial ownership of BIIB common stock. The amendment reflects an internal realignment that disaggregated certain subsidiary holdings under SEC Release No. 34-39538 on January 12, 2026.
Why did Vanguard file this Schedule 13G/A amendment for BIIB?
The amendment records an internal realignment dated January 12, 2026 under SEC Release No. 34-39538. It disaggregates beneficial ownership so former Vanguard subsidiaries report holdings separately rather than under The Vanguard Group, Inc.
Who signed the BIIB Schedule 13G/A amendment for Vanguard?
Ashley Grim, Head of Global Fund Administration, signed the filing on 03/26/2026. The signature block appears at the end of the amendment and provides the filer’s title and date.
Does the amendment identify any third parties with rights to BIIB dividends or proceeds?
The filing states Vanguard, including managed accounts, has the right to receive or direct dividends/proceeds, and no other single person holds more than 5%. It notes shareholder listings for investment companies or benefit plans are not required.